Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lumi804-Anti-PSMA
- Development stage
- Preclinical
- Lead developer
- Lumiphore
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lumi804-Anti-PSMA is a preclinical-stage radiotheranostic candidate developed by Lumiphore for the management of prostate cancer. The asset utilizes a monoclonal antibody specific to Prostate-Specific Membrane Antigen (PSMA), which is highly overexpressed in prostate cancer cells. This antibody is conjugated to Lumiphore's proprietary Lumi804 macrocyclic bifunctional chelate (mBFC). The Lumi804 platform is designed to stably bind various radioisotopes, allowing the same targeting vector to be used for both diagnostic imaging (when labeled with Zirconium-89 for PET) and therapeutic intervention (when labeled with Thorium-227 for targeted alpha therapy). This 'see-and-treat' approach facilitates patient selection and personalized dosimetry while delivering potent alpha radiation to tumor sites.
- Other names
- Lumi804 Anti-PSMA radiotheranosticLumi-804 Anti-PSMA radiotheranosticLumi 804 Anti-PSMA radiotheranostic
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Lumi804-Anti-PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lumi804-Anti-PSMA.